Adisyn (ASX: AI1) has surged into the ASX spotlight after breakthrough graphene chip technology, defence expansion, and strong institutional backing fuelled a massive share price rally, positioning the company as a highly speculative but fast-rising AI semiconductor play.
Elevra Lithium has surged over 400% amid stronger lithium prices, record revenue, and growing EV demand. Backed by North America’s largest hard-rock lithium mine, ELV remains technically bullish, with investors closely watching a breakout above A$14.20.
Develop Global (ASX: DVP) is gaining momentum as Woodlawn reaches steady-state production, Sulphur Springs economics improve, and mining services expand. Supported by strong copper and zinc markets, the company’s breakout reflects operational execution, contract growth, and multiple upcoming catalysts.
Megaport (ASX: MP1) shares surged over 35% after the company secured AI infrastructure contracts worth A$254 million through Latitude.sh, strengthening its position in the booming AI compute and cloud connectivity market.
Pacific Edge (ASX: PEB) tests critical resistance near 0.240 after surging on draft Medicare coverage, a 75% increase in reimbursement rates, and a NZ$25.4 million capital raise. Strong volume supports the rally, but RSI near 70 warns of potential pullback risk.
Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.
...
